vs
アレジオン（ALLE）とUNITED THERAPEUTICS Corp（UTHR）の財務データ比較。上の社名をクリックして会社を切り替えられます
アレジオンの直近四半期売上が大きい（$1.0B vs $790.2M、UNITED THERAPEUTICS Corpの約1.3倍）。UNITED THERAPEUTICS Corpの純利益率が高く（46.1% vs 13.4%、差は32.7%）。アレジオンの前年同期比売上増加率が高い（9.7% vs 7.4%）。過去8四半期でUNITED THERAPEUTICS Corpの売上複合成長率が高い（8.0% vs 3.5%）
アレジオン（Allegion plc）は世界中で機械式・電子式セキュリティ製品およびソリューションを製造販売している。取扱製品はドアクローザー、出入り口制御装置、錠前、電子入退室管理システム、勤怠管理システム、ドアシステムや各種付属部品など多岐にわたり、商業施設、公共施設、住宅などの顧客に提供している
ユナイテッド・セラピューティクスは米国のバイオテクノロジー企業で、異種移植を含む臓器移植関連の医薬品や技術を開発しています。主力製品の多くは肺疾患治療や臓器製造分野向けで、メリーランド州とノースカロライナ州に2つの本社を置き、米国各地やカナダにも拠点を構えています。
ALLE vs UTHR — 直接比較
損益計算書 — Q1 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.0B | $790.2M |
| 純利益 | $138.1M | $364.3M |
| 粗利率 | 44.0% | 86.9% |
| 営業利益率 | 18.9% | 45.1% |
| 純利益率 | 13.4% | 46.1% |
| 売上前年比 | 9.7% | 7.4% |
| 純利益前年比 | -6.8% | 20.9% |
| EPS（希薄化後） | — | $7.66 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $1.0B | — | ||
| Q4 25 | $1.0B | $790.2M | ||
| Q3 25 | $1.1B | $799.5M | ||
| Q2 25 | $1.0B | $798.6M | ||
| Q1 25 | $941.9M | $794.4M | ||
| Q4 24 | $945.6M | $735.9M | ||
| Q3 24 | $967.1M | $748.9M | ||
| Q2 24 | $965.6M | $714.9M |
| Q1 26 | $138.1M | — | ||
| Q4 25 | $147.5M | $364.3M | ||
| Q3 25 | $188.4M | $338.7M | ||
| Q2 25 | $159.7M | $309.5M | ||
| Q1 25 | $148.2M | $322.2M | ||
| Q4 24 | $144.1M | $301.3M | ||
| Q3 24 | $174.2M | $309.1M | ||
| Q2 24 | $155.4M | $278.1M |
| Q1 26 | 44.0% | — | ||
| Q4 25 | 44.5% | 86.9% | ||
| Q3 25 | 45.8% | 87.4% | ||
| Q2 25 | 45.6% | 89.0% | ||
| Q1 25 | 44.9% | 88.4% | ||
| Q4 24 | 44.1% | 89.7% | ||
| Q3 24 | 44.7% | 88.9% | ||
| Q2 24 | 44.4% | 89.1% |
| Q1 26 | 18.9% | — | ||
| Q4 25 | 20.3% | 45.1% | ||
| Q3 25 | 21.8% | 48.6% | ||
| Q2 25 | 21.5% | 45.6% | ||
| Q1 25 | 20.9% | 48.2% | ||
| Q4 24 | 19.5% | 48.6% | ||
| Q3 24 | 22.2% | 45.8% | ||
| Q2 24 | 21.6% | 44.7% |
| Q1 26 | 13.4% | — | ||
| Q4 25 | 14.3% | 46.1% | ||
| Q3 25 | 17.6% | 42.4% | ||
| Q2 25 | 15.6% | 38.8% | ||
| Q1 25 | 15.7% | 40.6% | ||
| Q4 24 | 15.2% | 40.9% | ||
| Q3 24 | 18.0% | 41.3% | ||
| Q2 24 | 16.1% | 38.9% |
| Q1 26 | — | — | ||
| Q4 25 | $1.70 | $7.66 | ||
| Q3 25 | $2.18 | $7.16 | ||
| Q2 25 | $1.85 | $6.41 | ||
| Q1 25 | $1.71 | $6.63 | ||
| Q4 24 | $1.65 | $6.23 | ||
| Q3 24 | $1.99 | $6.39 | ||
| Q2 24 | $1.77 | $5.85 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $308.9M | $2.9B |
| 総負債低いほど良い | $2.0B | — |
| 株主資本純資産 | $2.1B | $7.1B |
| 総資産 | $5.3B | $7.9B |
| 負債/資本比率低いほどレバレッジが低い | 0.97× | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $308.9M | — | ||
| Q4 25 | $356.2M | $2.9B | ||
| Q3 25 | $302.7M | $2.8B | ||
| Q2 25 | $656.8M | $3.0B | ||
| Q1 25 | $494.5M | $3.3B | ||
| Q4 24 | $503.8M | $3.3B | ||
| Q3 24 | $878.9M | $3.3B | ||
| Q2 24 | $747.5M | $3.0B |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.1B | $7.1B | ||
| Q3 25 | $1.9B | $6.6B | ||
| Q2 25 | $1.8B | $7.2B | ||
| Q1 25 | $1.6B | $6.8B | ||
| Q4 24 | $1.5B | $6.4B | ||
| Q3 24 | $1.6B | $6.1B | ||
| Q2 24 | $1.4B | $5.7B |
| Q1 26 | $5.3B | — | ||
| Q4 25 | $5.2B | $7.9B | ||
| Q3 25 | $5.2B | $7.4B | ||
| Q2 25 | $4.9B | $7.9B | ||
| Q1 25 | $4.6B | $7.7B | ||
| Q4 24 | $4.5B | $7.4B | ||
| Q3 24 | $5.0B | $7.1B | ||
| Q2 24 | $4.8B | $6.7B |
| Q1 26 | 0.97× | — | ||
| Q4 25 | 0.96× | — | ||
| Q3 25 | 1.07× | — | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.24× | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | 1.53× | — | ||
| Q2 24 | 1.69× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $101.3M | $346.2M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $173.3M |
| FCFマージンFCF / 売上 | — | 21.9% |
| 設備投資強度設備投資 / 売上 | 2.0% | 21.9% |
| キャッシュ転換率営業CF / 純利益 | 0.73× | 0.95× |
| 直近12ヶ月FCF直近4四半期 | — | $1.0B |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $101.3M | — | ||
| Q4 25 | $240.1M | $346.2M | ||
| Q3 25 | $229.5M | $562.1M | ||
| Q2 25 | $209.7M | $191.7M | ||
| Q1 25 | $104.5M | $461.2M | ||
| Q4 24 | $219.0M | $341.2M | ||
| Q3 24 | $231.9M | $377.2M | ||
| Q2 24 | $173.0M | $232.2M |
| Q1 26 | — | — | ||
| Q4 25 | $200.5M | $173.3M | ||
| Q3 25 | $209.8M | $351.6M | ||
| Q2 25 | $192.0M | $129.5M | ||
| Q1 25 | $83.4M | $386.3M | ||
| Q4 24 | $194.9M | $254.5M | ||
| Q3 24 | $212.0M | $300.7M | ||
| Q2 24 | $152.1M | $187.1M |
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | 21.9% | ||
| Q3 25 | 19.6% | 44.0% | ||
| Q2 25 | 18.8% | 16.2% | ||
| Q1 25 | 8.9% | 48.6% | ||
| Q4 24 | 20.6% | 34.6% | ||
| Q3 24 | 21.9% | 40.2% | ||
| Q2 24 | 15.8% | 26.2% |
| Q1 26 | 2.0% | — | ||
| Q4 25 | 3.8% | 21.9% | ||
| Q3 25 | 1.8% | 26.3% | ||
| Q2 25 | 1.7% | 7.8% | ||
| Q1 25 | 2.2% | 9.4% | ||
| Q4 24 | 2.5% | 11.8% | ||
| Q3 24 | 2.1% | 10.2% | ||
| Q2 24 | 2.2% | 6.3% |
| Q1 26 | 0.73× | — | ||
| Q4 25 | 1.63× | 0.95× | ||
| Q3 25 | 1.22× | 1.66× | ||
| Q2 25 | 1.31× | 0.62× | ||
| Q1 25 | 0.71× | 1.43× | ||
| Q4 24 | 1.52× | 1.13× | ||
| Q3 24 | 1.33× | 1.22× | ||
| Q2 24 | 1.11× | 0.83× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ALLE
| Allegion Americas | $809.9M | 78% |
| Allegion International | $223.7M | 22% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
